Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	20.39B
Revenue (ttm)	7.06B
Net Income (ttm)	780.21M
Shares Out	2.47B
EPS (ttm)	0.31
PE Ratio	26.70
Forward PE	16.18
Dividend	0.17 (1.94%)
Ex-Dividend Date	Jun 18, 2025

Volume	1,116,000
Average Volume	8,058,125
Open	8.66
Previous Close	8.24
Day's Range	8.36 - 8.58
52-Week Range	5.08 - 9.19
Beta	0.45
RSI	48.22
Earnings Date	May 8, 2025

About HKG:2096

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,584
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2024, HKG:2096's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY